We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Hemoglobin Modifier Enhances RT in Advanced NSCLC

Jul 1, 2002
Volume: 
11
Issue: 
7
  • Lung Cancer

ORLANDO—Patients with locally advanced, un1resectable, non-small-cell lung
cancer (NSCLC) who received the radiation enhancer RSR13 (efaproxiral) along
with thoracic radiation therapy (RT) had a median survival of more than 20
months, according to a phase II study presented at the 38th Annual Meeting of
the American Society of Clinical Oncology (abstract 1236).

Mechanism of Action

Malignant tumors often have a poorly regulated blood supply
caused by disorganized growth of new blood vessels into the tumor. This leads
to the formation of hypoxic regions in the tumor. Hypoxic tumors are
substantially more resistant to radiation therapy than oxygenated tumors.

After picking up oxygen in the lungs and circulating to
various tissues in the body, each hemoglobin protein releases one of its four
oxygen molecules on average and retains the other three in reserve. RSR13 binds
to hemoglobin and changes the structure of the hemoglobin protein, resulting in
increased unloading of oxygen from hemoglobin to the hypoxic tissues.

The fact that RSR13 does not have to enter the cancer cell
to be effective is an important difference between RSR13 and other attempts to
improve radiation therapy, according to Allos Therapeutics. The oxygen released
diffuses across the cancer cell membrane to oxygenate the tumor. Radiation is
applied to the now oxygenated tumor, enhancing its effects.

RSR13 is a synthetic small molecule that increases the release of oxygen
from hemoglobin by reducing hemoglobin oxygen binding affinity. By increasing
tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard
radiation therapy (see box). It is being developed by Allos Therapeutics, Inc.,
Westminster, Colorado.

The open-label, multicenter phase II study included 49 evaluable patients
who received two courses of induction chemotherapy with paclitaxel (Taxol) 225
mg/m² and carboplatin (Paraplatin) to AUC 6 every 3 weeks for two cycles,
followed by thoracic radiation therapy with concurrent daily infusion of RSR13
for 32 doses.

With a median follow-up of 22.9 months, median survival was 20.6 months,
1-year survival was 67%, and 2-year survival was estimated at 35%. Grade 3-4
toxicities included transient hypoxemia (16%) and radiation pneumonitis (12%),
but no esophagitis, the researchers said.

"NSCLC can be aggressive and very difficult to treat," said
Abdenour Nabid, MD, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke,
Quebec, who presented the study at a poster session. "The combination of
RSR13 and thoracic radiation therapy was very well tolerated by these
patients."

Hak Choy, MD, clinical director, Center for Radiation Oncology,
Vanderbilt-Ingram Cancer Center, Nashville, was the principal investigator for
the study. "A median survival of 20.6 months continues to be very
encouraging, considering that the results from the relevant comparison group
for this study (the LAMP trial, ASCO abstract 1160, arm 1) showed 12.5 months
for the identical treatment, minus RSR13," Dr. Choy commented.

Allos Therapeutics is preparing a protocol for a phase III clinical study of
RSR13 in patients with stage III NSCLC. Currently, the company is conducting a
pivotal phase III randomized study evaluating the safety and efficacy of RSR13
and whole brain radiation therapy in patients with brain metastases.

Related Articles

  • Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLC
  • Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLC
  • Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.